Source: BIO 311C Lecture Notes, University of Texas at Austin
Difficulty: Intermediate | Prerequisites: Cell Cycle Control and Checkpoints notes (Part 1), understanding of cyclins, Cdks, and checkpoints.
Tags: cancer, oncogene, proto-oncogene, tumor suppressor, p53, Ras, metastasis, malignant tumor, benign tumor, growth factor autonomy, apoptosis resistance, telomerase, de-differentiation, cell cycle dysregulation, BIO 311C
Cancer is what happens when the cell cycle control system breaks down. Every checkpoint, growth-factor pathway, and regulatory protein covered in the Cell Cycle Control notes exists to prevent uncontrolled division, and cancer bypasses them. This section covers the molecular mechanisms behind that breakdown: how normal genes become cancer-promoting oncogenes, how tumour suppressor genes fail, and how the accumulation of mutations turns a single rogue cell into a life-threatening disease. You need to understand the normal cell cycle controls before this material makes sense.
Cancer cells are normal cells that have accumulated mutations allowing them to ignore the body's "stop dividing" signals. They may produce their own growth factors, resist apoptosis, and bypass checkpoints. The disease typically requires multiple mutations stacking up over time, which is why cancer incidence increases with age.
Proto-oncogene
A normal gene that codes for a protein involved in cell growth, division, or survival signalling. When mutated or overexpressed, it becomes an oncogene. Think of it as a normal accelerator pedal in a car.
Oncogene
A mutated or overexpressed version of a proto-oncogene that promotes uncontrolled cell division. In simple terms, the accelerator pedal is stuck down.
Tumour suppressor gene
A gene whose protein product normally inhibits cell division, promotes apoptosis, or repairs DNA damage. When both copies are inactivated by mutation, the cell loses a critical brake on proliferation. Think of it as the brake pedal: lose it, and the car will not stop.
p53
A tumour suppressor protein ("guardian of the genome") that responds to DNA damage by halting the cell cycle or triggering apoptosis. Mutations in p53 are found in roughly half of all human cancers. In simple terms, p53 is the cell's emergency stop button.
Ras
A proto-oncogene that encodes a G-protein involved in relaying growth factor signals from the cell surface to the nucleus. When mutated to a permanently active form, Ras continuously signals the cell to divide, regardless of whether a growth factor is present. Think of it as a relay switch stuck in the "on" position.
Metastasis
The process by which cancer cells spread from their original site to other parts of the body via the lymphatic system or bloodstream, forming secondary tumours. In simple terms, the cancer breaks loose and sets up shop elsewhere.
Malignant tumour
A mass of abnormal cells that can invade neighbouring tissues and metastasise. This distinguishes it from a benign tumour, which stays in place. In simple terms, malignant means the tumour is dangerous and can spread.
De-differentiation
The process by which cancer cells lose the specialised features of the tissue they came from, reverting to a more generic, immature cell state. In simple terms, the cell forgets what it was supposed to be.
Cancer cells are released from the normal controls of the cell cycle.
They originate from a single cell that has undergone critical mutations (cancer is clonal).
Cancer cells are de-differentiated: they lose the specialised structure and function of their tissue of origin.
They display abnormal shapes, behaviour, nuclei, and chromosome number or structure.
Normal cells require external growth factors to divide. Cancer cells do not.
Cancer cells may achieve growth-factor independence in several ways:
Producing their own growth factors (autocrine signalling)
Conveying a growth factor's signal downstream without the growth factor actually being present (constitutively active receptor or relay protein)
Having an abnormal cell cycle control system that bypasses checkpoints
In normal cells, growth factors regulate growth, proliferation, and survival. In cancer, all three of these are deregulated.
Growth signal autonomy: the cell generates its own proliferation signals.
Insensitivity to anti-growth signals: the cell ignores signals that would normally halt division.
Resistance to apoptosis: the cell refuses to self-destruct when it should.
Uncoupling from environmental signals: the cell's growth programme no longer responds to its surroundings.
Cancer development involves two categories of genes:
Proto-oncogenes (when mutated, become oncogenes): these normally promote cell growth and division. A gain-of-function mutation makes them permanently active.
Tumour suppressor genes: these normally restrain cell division or promote apoptosis. A loss-of-function mutation (typically in both copies) removes the brake.
Key pathways:
Ras pathway: Ras is a G-protein relay in the growth factor signalling chain. When mutated, Ras stays permanently "on," telling the cell to keep dividing regardless of external signals.
p53 pathway: p53 normally responds to DNA damage by pausing the cell cycle (giving time for repair) or triggering apoptosis (if damage is irreparable). Loss of p53 means damaged cells continue to divide, accumulating further mutations.
Multiple mutations are generally needed for a full malignancy. This is why cancer incidence increases with age: mutations stack up over a lifetime.
A tumour typically grows from a single cancer cell through repeated division.
Cancer cells invade neighbouring tissue, breaking through the normal boundaries that contain healthy cells.
Metastasis occurs when cancer cells enter the lymphatic system or bloodstream and travel to distant sites, where they may establish secondary tumours.
Only a small percentage of circulating cancer cells successfully metastasise, but those that do are responsible for most cancer deaths.
Traditional chemotherapy affects the entire body and often causes significant side effects because it targets all rapidly dividing cells, not just cancer cells.
Newer targeted therapies are designed to address the specific mutations present in a patient's cancer cells rather than targeting an organ type.
Targeted therapies are potentially more effective and less damaging to healthy tissue.
Students often think a single mutation causes cancer. In most cases, multiple mutations must accumulate in the same cell lineage before it becomes fully malignant. One mutation alone is rarely enough.
It is common to confuse oncogenes and tumour suppressors. Remember: an oncogene is a gas pedal stuck on (gain of function). A tumour suppressor is a brake that has been removed (loss of function). They are opposite kinds of failure.
Students sometimes believe that benign tumours are "pre-cancer." A benign tumour stays in place and does not invade or metastasise. While some benign tumours can progress, the terms are not interchangeable.
Many students assume that chemotherapy targets only cancer cells. It does not. Traditional chemo targets all rapidly dividing cells, which is why it causes hair loss, immune suppression, and gastrointestinal problems.
Be able to distinguish proto-oncogenes from oncogenes, and explain the difference in terms of gain-of-function vs. loss-of-function mutations.
Know the Ras and p53 pathways in detail. Ras = growth factor relay stuck on. p53 = DNA damage response removed. These are the two most commonly tested examples.
Understand why cancer requires multiple mutations ("multi-hit hypothesis") and how this explains the age-related increase in cancer incidence.
Be prepared to explain the four hallmarks of cancer signalling covered in this lecture: growth signal autonomy, insensitivity to anti-growth signals, resistance to apoptosis, and uncoupling from environmental signals.
Know the difference between traditional chemotherapy (targets all rapidly dividing cells) and targeted therapy (targets specific mutations in cancer cells).
True or False: An oncogene is a normal gene that has been turned off. (False. An oncogene is a mutated proto-oncogene that is stuck in an active, growth-promoting state.)
Fill in the blank: The tumour suppressor protein known as the "guardian of the genome" is ________. (p53)
True or False: A single mutation is usually sufficient to cause cancer. (False. Multiple mutations must accumulate over time.)
Fill in the blank: When cancer cells spread from their original site to distant organs via the bloodstream, this process is called ________. (metastasis)
True or False: Cancer cells typically need external growth factors to divide. (False. Cancer cells can often produce their own growth factors or signal without them.)
Q: Compare and contrast oncogenes and tumour suppressor genes. How does each contribute to cancer when mutated?
A: Proto-oncogenes are normal genes that promote cell growth. When mutated, they become oncogenes: permanently active, driving the cell to divide without restraint (gain of function). Tumour suppressor genes normally inhibit division or trigger apoptosis. When both copies are lost or inactivated, the cell loses its braking mechanism (loss of function). Cancer typically involves both types of mutation working together.
Q: Explain how a mutation in the Ras gene can lead to uncontrolled cell division.
A: Ras is a relay protein in the growth factor signalling pathway. Normally, Ras is activated only when a growth factor binds its receptor. A mutation can lock Ras into its active conformation permanently, so it continuously sends "divide" signals to the nucleus regardless of whether a growth factor is present.
Q: Why does the loss of p53 function contribute to cancer development?
A: p53 normally detects DNA damage and either pauses the cell cycle to allow repair or triggers apoptosis if the damage is too severe. Without functional p53, cells with damaged DNA continue to divide, passing on and accumulating further mutations that drive cancer progression.
Q: Explain why cancer incidence increases with age.
A: Cancer typically requires multiple mutations to accumulate in the same cell lineage (the multi-hit model). Over a lifetime, cells experience more rounds of division and more exposure to mutagens, so the probability of stacking enough mutations to produce a cancer cell increases with age.
Q: How does targeted cancer therapy differ from traditional chemotherapy?
A: Traditional chemotherapy targets all rapidly dividing cells in the body, causing widespread side effects. Targeted therapy is designed to act on specific molecular pathways or mutations present in the patient's cancer cells, making it potentially more effective and less harmful to healthy tissue.
This material builds directly on the Cell Cycle Control and Checkpoints notes: every cancer hallmark here is a specific failure of a control mechanism covered there. It connects forward to gene regulation and signal transduction topics, where the Ras and p53 pathways are explored in greater molecular detail. The concept of mutations accumulating over time ties into DNA repair mechanisms and mutagenesis, and the role of telomerase links back to DNA replication and chromosome biology.
cancer, tumour, tumor, oncogene, proto-oncogene, tumour suppressor gene, tumor suppressor gene, p53, guardian of the genome, Ras, Ras pathway, growth factor autonomy, growth signal autonomy, anti-growth signals, apoptosis, apoptosis resistance, metastasis, malignant, benign, de-differentiation, multi-hit hypothesis, mutation accumulation, chemotherapy, targeted therapy, PDGF, signal transduction, cell cycle dysregulation, uncontrolled cell division, telomerase, immortal cells, BIO 311C, intro biology, University of Texas Austin